Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials

Published:2017-04-12 Issue:6 Volume:98 Page:601-607
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Sheng Zhixin¹^ORCID,Li Guifang²,Li Bin³,Liu Yanju⁴,Wang Lida⁵

Affiliation:

1. Department of Hematology; Weifang People's Hospital; Weifang China

2. Department of Occupational Disease; Weifang People's Hospital; Weifang China

3. Department of Respiration; Weifang People's Hospital; Weifang China

4. Department of Infection; Weifang People's Hospital; Weifang China

5. E.N.T. department; Weifang People's Hospital; Weifang China

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12877/fullpdf

Reference20 articles.

1. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study;Kumar;Leukemia,2012

2. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome;Demo;Cancer Res,2007

3. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma;Kuhn;Blood,2007

4. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome;Parlati;Blood,2009

5. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma;Stewart;N Engl J Med,2015

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polypharmacology in Old Drug Rediscovery: Drug Repurposing;Polypharmacology;2022

2. Therapeutic Repurposing of Antiviral Drugs Available for COVID-19 Therapy: A Mini Review;Asian Journal of Chemistry;2022

3. Epidemiology, Staging, and Management of Multiple Myeloma;Medical Sciences;2021-01-20

4. Repurposing anticancer drugs for the management of COVID-19;European Journal of Cancer;2020-12

5. Options for Chemotherapy and Scoring Response and Relapse;Hematology/Oncology Clinics of North America;2020-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3